Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant ...

VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...

Just when you had written off biotech stocks as boring, here comes the MIT Technology Review to name its “Three technologies ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...